Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Response to Senate Finance Committee Minority…
BIO Letter on AR HB1531
BIO Comments to Pharmacy Compounding Advisory…
All Letters, Testimony & Comments
  • Show All
Search
Results
March 10, 2016
BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal
March 10, 2016
BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.
March 10, 2016
Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.
March 10, 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.
March 10, 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.
March 10, 2016
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…
March 10, 2016
BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.
February 18, 2016
We, the undersigned organizations, appreciate the opportunity to provide comment on APHIS’ Notice of Intent (NOI) to prepare an environmental impact statement in connection with potential changes to APHIS biotechnology regulations (7 CFR 340). Our…
February 8, 2016
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the 2016 Special 301 Submission.